Looks like our new COO is in the states learning the ropes this week.
It won't surprise me at all if we get word of the initiation of CHM 2101 any day now. On the clinical trial website, the trials original estimated start date was May. That was changed early this year to mid year. No coincidence it aligns with Jens departure.
From LinkedIn.Congratulations and welcome Rebecca!
Eliot BourkView Eliot Bourk’s profile• 3rd+Chief Business Officer at Chimeric Therapeutics